Novavax reports respiratory tract vaccine success

Respiratory tract vaccine trial a success, Novavax indicates.

Pharmaceutical company Novavax has announced its latest trials for a vaccine designed to treat respiratory tract infections in women of childbearing age have been deemed a success, with a positive response in all participants of the mid-stage trial.
According to the company, 330 women tested 60 microgram and 90 microgram doses of the vaccine, with either one or two injections received, or a placebo.
The most positive results were found in those patients who also received an adjuvant, an agent designed to boost immune response.
MLV & Co analyst George Zavoico explained to Reuters that the 60 microgram dosage proved to be confirmatory of the vaccine's effectiveness.
"They will go with an adjuvant and will probably go forward testing two doses administered a month apart, because the greatest response was with using a two-dose regimen," he added.
The next phase of the clinical trial will see how animals and elderly people respond to the treatment, with a view to eventually observing the response in pregnant women.